Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors
The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds.
Boston Biomedical, Inc.
A A Y A A A A A A A A C A A A C A A A A A A A A A A A A
A61P A61P Y02A A61P A61P A61P A61P A61P A61P A61P A61P C07D A61P A61P A61P C07D A61P A61P A61P A61P A61P A61K A61P A61P A61K A61P A61P A61P
inventional inventional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Jifeng Harry Youzhi Chiang Jia Wei
Liu Rogoff Li Li Li